Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital

Enrigue Chacon-Cruz; R M Rivas-Landeros; M L Volker-Soberanes

doi:10.1177/2051013614547199

Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital

Ther Adv Vaccines. 2014 Nov;2(6):155-8. doi: 10.1177/2051013614547199.

Authors

Enrigue Chacon-Cruz¹, R M Rivas-Landeros², M L Volker-Soberanes²

Affiliations

¹ Pediatric Infectious Diseases Service, Hospital General de Tijuana, Tijuana Baja-California, Paseo Centenario S/N, Zona Rio, Tijuana, Baja-California, ZC 22010, Mexico.
² Microbiology Laboratory, Hospital General de Tijuana, Tijuana Baja-California, Mexico.

Abstract

Background: In May 2012, universal vaccination with the 13-valent pneumococcal conjugate vaccine (PCV-13) was introduced for all children in the Tijuana region of Mexico, with a coverage of 80%.

Method: Between October 2005 and September 2013 active surveillance was undertaken for all invasive pneumococcal diseases (IPDs) in children admitted to the Tijuana General Hospital.

Results: Following PCV-13 implementation, there was a 75% reduction in overall IPD, and no cases of serotype 19A, pneumococcal meningitis, and pneumococcal-associated deaths.

Conclusions: These results are the first to show the effectiveness of PCV-13 in Mexico.

Keywords: mexico; pneumococcal diesase; pneumococcal vaccine; streptococcus pneumoniae; vaccine effectiveness.